A World Class Team

We develop innovative pharmaceutical products in the oncology space focusing on women’s and pediatric drugs.

Shorla Pharma was founded by two healthcare entrepreneurs, Sharon Cunningham and Orlaith Ryan who have a combined experience of over 20 years in the pharmaceutical space having worked together in Senior positions at EirGen Pharma in Waterford, Ireland

Executive Team

Sharon Cunningham
Co-founder & Co-CEO

Sharon co-founded Shorla Pharma in 2018 and leads the Fundraising and commercialization activities. She has vast experience in equity and debt financing and M&A in the pharmaceutical space. Sharon is a PwC qualified Chartered Accountant with a BSc in Finance and holds an MBA from University College Dublin Smurfit School. Sharon also sits on the Board of Irish Rule of Law International.

Orlaith Ryan
Co-founder & Co-CEO

Orlaith co-founded Shorla Pharma in 2018 and leads the product development programs and supply chain activities. She has vast experience in the life sciences industry, having worked previously in product development, regulation and compliance. Orlaith is a Chartered Scientist, a Biochemist and holds an MSc in Regulatory Affairs from the University of Wales.

Victoria Power
Head of Operations

Victoria leads the operations team at Shorla Pharma. Having previously held leadership positions at companies such as Novartis and ICON plc, her extensive experience spans programme management, clinical trial operations oversight and product commercialization for both large and small pharma. Victoria has led the development and commercialization of new products in global markets and their associated life cycle management. Victoria has a BSc from University College Dublin and is PRINCE 2 qualified.

 

John Doherty
Head of Quality

John joined Shorla Pharma in 2020 and leads the quality operations. He has extensive, practical, and up to date international pharmaceutical experience over 30 years, where he has held senior quality operations positions. John was involved in the start up, and expansions, of both Actavis, as Director of Quality at the Dupnitza, Bulgaria site, and with Alvogen as VP of Quality. John is registered to act as an EU QP in Ireland. John has a BSc and PhD from University College Dublin, and an MBA from Brunel University, London.

Advisory Team

Roland Turck, MD
Commercial Advisor

Dr Roland Turck is Managing Partner of TurckBio, an international consulting firm focused on corporate strategy as well as on clinical and commercial strategies in oncology and other specialty medicine areas. Before founding TurckBio, Roland gained 25+ years of operational experience as senior biopharm executive in a variety of roles such as President of the Global Specialty Medicine Business Unit at Bayer and as co-founder of an oncology biotech company.

Dr. Martin F. Bexon MBBS
Clinical Advisor

Martin, a UK- and NZ-trained MD, has worked in pharma for 17 years and held positions in the UK, Switzerland and the US leading clinical development programs in oncology, immunology and internal medicine. He has a broad base of experience in the clinic, in early and late clinical development, in medical affairs and across multiple therapy areas. He provides clinical and regulatory expertise to shape projects strategically and a hands-on approach to clinical development, with extensive involvement in study design, preparation of protocols and the key interactions with health authorities.

John H. Sampson, MD
Clinical Advisor

John H. Sampson, MD, PhD, is the Robert H. and Gloria Wilkins Distinguished Professor, inaugural chair of the Department of Neurosurgery at Duke University, and the most highly funded PI in neurosurgery by the NIH. In March 2020 he was named president of the Private Diagnostic Clinic, Duke Health’s physician practice of 1,850 providers and 140 clinics. He is a neurosurgeon-scientist who develops novel drugs for patients with brain tumors and focuses on the development, translation, and mechanistic understanding of immunotherapies.